Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jun 17, 2019
High probability bearish signal on Cronos Group (CRON)

High probability bearish signal on Cronos Group (CRON)

Cronos Group (Nasdaq: CRON) is a rather unique company. It is considered a healthcare company as far as its sector designation, but it considers itself to be an investment firm that invests in medical marijuana companies. Cannabis investing has been a prominent storyline over the last few years and that has helped the stock move up sharply in the last two years.

Despite the rally, the stock has been trending lower in the last four and a half months. A trend channel has formed that defines the cycles within the overall trend. This channel is different in the way that I drew it because it was the lower rail that stood out to me first. I connected the lows from February, March, April, and May to form the lower rail. I then drew a parallel line and used the high from March as the starting point. What we see on the chart below is that the stock just hit the upper rail of the channel and then turned lower.

We see that the stock was overbought based on the daily stochastic readings, but the indicators turned lower and made a bearish crossover on June 13.

The Tickeron Trend Prediction Engine generated a bearish signal on the same day as the stochastics crossover. The signal showed a confidence level of 89% and past predictions on the stock have been successful 88% of the time. The signal calls for a drop of at least 4% over the next month.

Related Ticker: CRON

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


CRON in upward trend: price rose above 50-day moving average on August 06, 2026

CRON moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend. In of 70 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on CRON as a result. In of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CRON just turned positive on August 06, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRON moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where CRON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRON broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.158) is normal, around the industry mean (46.981). P/E Ratio (17.684) is within average values for comparable stocks, (93.748). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.226). CRON has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (7.143) is also within normal values, averaging (176.812).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.12B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 33%. EBS experienced the highest price growth at 16%, while IMCC experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -23% and the average quarterly volume growth was 44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 54
SMR Rating: 88
Profit Risk Rating: 82
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
CRON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

pharmaceutical, medical marijuana, cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Other
Address
4491 Concession Rd 12
Phone
+1 416 504-0004
Employees
610
Web
https://www.thecronosgroup.com
Interact to see
Advertisement
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
GDDY (GoDaddy) is down more than 17% today because its 2026 revenue outlook and near‑term sales guidance came in below Wall Street expectations, reinforcing worries about slowing growth and intense AI‑driven competition even though Q4 2025 headline results were solid.
For the first half of fiscal 2026, organic net sales and adjusted EPS both declined about 3% year over year and missed analyst expectations, with U.S. spirits and Chinese white spirits particularly weak. Management cut full‑year 2026 guidance again, now expecting organic sales to fall 2–3% and organic operating profit to be flat to up only low single digits, versus a prior outlook of flat to slightly down sales and low‑ to mid‑single‑digit profit growth.
DRVN (Driven Brands) is down more than 36% today because the company disclosed serious errors in its past financial statements, is delaying its Q4 2025 earnings release, and will have to restate results for the last two fiscal years, which shattered investor confidence and raised concerns about leverage and profitability.
Q4 2025 revenue was strong at about 257–258 million (up roughly 16% year over year and above forecasts), but adjusted EPS was 0.30 versus about 0.31–0.32 expected, and EBITDA of about 101–102 million was a touch below consensus.
Q4 2025 revenue was about 392 million, roughly 10–20% below consensus (around 430–440 million), and EPS came in at −0.44−0.44 versus forecasts near −0.27−0.27 to −0.32−0.32, a more than 60% negative surprise. Results were hit by a roughly 170 million non‑cash impairment plus weaker realized pricing and volumes, driving a large net loss in the quarter despite strong full‑year EBITDA and free cash flow.
AXON surged approximately +17.56% on February 25, 2026, closing at $520.18 versus the prior session's close of $442.51. The primary catalyst was a blowout Q4 2025 earnings report, with adjusted EPS of $2.15 crushing the consensus estimate of approximately $1.67.
CAVA shares surged approximately +25.01% on February 25, 2026, closing near $84.76, up from the prior session's close of $67.80. The primary catalyst was a better-than-expected Q4 fiscal 2025 earnings report, with EPS of $0.04 beating the $0.03 consensus estimate and revenue of ~$274.99M exceeding the $268.04M estimate.
ODD shares plunged approximately 49.21% on February 25, 2026, closing near $14.74, compared to the prior close of approximately $29.02. The primary catalyst was a shock Q1 2026 revenue warning: management guided for a roughly 30% year-over-year revenue decline due to a severe spike in customer acquisition costs (CAC).
MNKD shares collapsed 36.82% on February 25, 2026, closing at $3.50 versus the prior session's close of $5.54 — one of the largest single-day declines in the stock's recent history. The primary catalyst was United Therapeutics' surprise unveiling of Tresmi, a proprietary soft mist inhaler delivering treprostinil, announced during the company's Q4 2025 earnings call.
EOSE shares fell sharply on February 26, 2026, dropping approximately 31% from the prior session's close of $11.13 to around $7.64 in early trading, following a pre-market earnings release. Primary catalyst: Eos Energy reported Q4 2025 non-GAAP EPS of -$0.72, missing analyst consensus estimates by $0.48, a 200%+ negative surprise.
ARRY beat Q4 revenue expectations but showed a sharp year‑over‑year sales decline and a sizeable net loss. Adjusted EBITDA for Q4 badly missed Wall Street estimates, highlighting ongoing margin and cost pressures. 2026 guidance for EPS and EBITDA came in well below analyst forecasts, signaling weaker‑than‑hoped earnings power over the next year.
C3.ai (AI) dropped more than 18% today after delivering a deeply disappointing quarterly report, slashing its revenue outlook, and announcing mass layoffs, which together reinforced doubts about its growth story in an increasingly competitive AI software market.
On the surface, PRCT’s top line still grew: Q4 2025 revenue reached about 76.4 million dollars, up roughly 11.9–12% from the prior year. However, analysts had expected something closer to 94–96 million dollars, so the shortfall of nearly 20% was significant for a high‑growth med‑tech name.
Payoneer Global (PAYO) fell more than 18% today after it missed Wall Street expectations on both Q4 2025 revenue and earnings, and issued softer‑than‑hoped guidance that reinforced concerns about slowing growth and competitive pressure in cross‑border fintech.
Gold, uranium, and rare earth stocks are moving fast in 2026 — and this 15-minute AI Trading Agent is built to move faster. Designed for high-beta Mining & Metals leaders like NEM, LEU, MP, and KGC, it transforms commodity volatility into structured, data-driven opportunity with institutional-grade risk control.